KMT2A and leukemia: Recently, highly potent and selective inhibitors of the Menin-MLL interaction such as VTP50469 and MI-3454 have been developed and have shown remarkable preclinical efficacy in MLL1-rearranged and NPM1-mutated leukemia in vivo models [25, 28–31].